Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8865688 | VALEANT PHARMS INTL | Compositions and methods for treatment of bowel diseases with granulated mesalamine |
May, 2030
(7 years from now) |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 31 October, 2008
Treatment: For the maintenance of remission of ulcerative colitis
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
5
United States
1
Ukraine
1
South Africa
1
Australia
1
Chile
1
New Zealand
1
Israel
1
Canada
1
Mexico
1
EA
1
China
1
Japan
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7625884 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(3 years from now) | |
US7452872 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(3 years from now) | |
US7625884
(Pediatric) | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Feb, 2027
(4 years from now) | |
US7452872
(Pediatric) | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Feb, 2027
(4 years from now) |
Drugs and Companies using BALSALAZIDE DISODIUM ingredient
Market Authorisation Date: 18 July, 2000
Treatment: Treatment of ulcerative colitis
Dosage: CAPSULE;ORAL
10
United States
6
Japan
5
China
4
Canada
4
European Union
3
New Zealand
2
Korea, Republic of
2
Brazil
2
Australia
2
Israel
2
Mexico
1
Denmark
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9192616 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(3 years from now) | |
US7452872 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(3 years from now) | |
US7625884 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Aug, 2026
(3 years from now) | |
US8497256 | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males |
Jun, 2031
(8 years from now) |
Drugs and Companies using BALSALAZIDE DISODIUM ingredient
Market Authorisation Date: 03 February, 2012
Treatment: Treatment of mildly to moderately active ulcerative colitis in male patients
Dosage: TABLET;ORAL
15
United States
7
Japan
5
China
5
Canada
5
European Union
4
Brazil
3
Australia
3
New Zealand
3
Mexico
2
Korea, Republic of
2
Israel
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic